OS Therapies (OSTX) vs Rafael (RFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rafael (RFL) has outperformed OS Therapies (OSTX) over the past year, gaining 9.6% versus a loss of 20.6%. Rafael is the larger company by market cap ($77.0 million vs $75.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSTX | RFL |
|---|---|---|
| Share price | $1.62 | $1.48 |
| Market cap | $75.82M | $76.96M |
| 1-day change | +4.52% | 0.00% |
| YTD return | +15.71% | +25.42% |
| 1-year return | -20.59% | +9.63% |
| 5-year return | — | -95.09% |
| Forward P/E | 4.67 | — |
| EPS (TTM) | $-1.08 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $3.96 |
| 52-week low | $1.15 | $1.12 |
| Distance from 52-week high | -28.00% | -62.63% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +424.69% | — |
| Average volume | 586.70K | 159.84K |
| Shares outstanding | 46.81M | 51.21M |
| Employees | 4 | 21 |
| Sector | Healthcare | Real Estate |
| Industry | Biotechnology | Real Estate Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RFL has outperformed OSTX by 30.2 percentage points over the past year.
- The two companies sit in different sectors: OS Therapies in Healthcare and Rafael in Real Estate.
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Healthcare · Biotechnology · 4 employees
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Real Estate · Real Estate Services · 21 employees
OSTX vs RFL FAQ
Which is bigger, OS Therapies or Rafael?
Rafael (RFL) is larger, with a market capitalization of $76.96M compared with $75.82M for OS Therapies (OSTX).
Which stock has performed better over the past year, OSTX or RFL?
RFL returned +9.63% over the past 12 months, compared with -20.59% for OSTX (price return, excluding dividends). Past performance does not predict future results.
Are OS Therapies and Rafael in the same industry?
No. OS Therapies is in the Healthcare sector, while Rafael is in Real Estate.